DURHAM – Tellus Therapeutics, the neonatal care startup based in Durham, is raising a new round of funding and is almost halfway to its goal of $35 million.

That’s according to an  SEC filing.

Tellus raised $35 million late last year as it continues in efforts to advance treatments for newborn children in neonatal intensive care unit.

According to the latest filing

Tellus landed $15,999,999 from a single investor.

Durham biotech startup Tellus secures $35M Series A to advance treatment for babies in the NICU

With $2M in hand, neonatal startup Tellus Therapeutics plans future raise